ZVRAZevra Therapeutics, Inc.

$559M

Q3 2019 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$11M

Gross Profit

$10M91.3% margin

Operating Income

$3M28.2% margin

Net Income

$3M23.7% margin

EPS (Diluted)

$0.96

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$2M

Free Cash Flow

-$2M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$13M

Total Liabilities

$84M

Stockholders' Equity

-$71M

Cash & Equivalents

$7M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$11M	$0	—
Gross Profit	$10M	$0	—
Operating Income	$3M	-$18M	+118.0%
Net Income	$3M	-$15M	+118.0%

ZVRA Q3 2019 Earnings — Zevra Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena